Literature DB >> 18940813

Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation.

Ryan T Nitta1, Albert H Chu, Albert J Wong.   

Abstract

c-Jun N-terminal kinases (JNKs) are part of the mitogen-activated protein kinase (MAPK) family and are important regulators of cell growth, proliferation, and apoptosis. Typically, a sequential series of events are necessary for MAPK activation: phosphorylation, dimerization, and then subsequent translocation to the nucleus. Interestingly, a constitutively active JNK isoform, JNK2alpha2, possesses the ability to autophosphorylate and has been implicated in several human tumors, including glioblastoma multiforme. Because overexpression of JNK2alpha2 enhances several tumorigenic phenotypes, including cell growth and tumor formation in mice, we studied the mechanisms of JNK2alpha2 autophosphorylation and autoactivation. We find that JNK2alpha2 dimerization in vitro and in vivo occurs independently of its autophosphorylation but is dependent on nine amino acids, known as the alpha-region. Alanine scanning mutagenesis of the alpha-region reveals that five specific mutants (L218A, K220A, G221A, I224A, and F225A) prevent JNK2alpha2 dimerization rendering JNK2alpha2 inactive and incapable of stimulating tumor formation. Previous studies coupled with additional mutagenesis of neighboring isoleucines and leucines (I208A, I214A, I231A, and I238A) suggest that a leucine zipper may play an important role in JNK2alpha2 homodimerization. We also show that a kinase-inactive JNK2alpha2 mutant can interact with and inhibit wild type JNK2alpha2 autophosphorylation, suggesting that JNK2alpha2 undergoes trans-autophosphorylation. Together, our results demonstrate that JNK2alpha2 differs from other MAPK proteins in two major ways; its autoactivation/autophosphorylation is dependent on dimerization, and dimerization most likely precedes autophosphorylation. In addition, we show that dimerization is essential for JNK2alpha2 activity and that prevention of dimerization may decrease JNK2alpha2 induced tumorigenic phenotypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940813      PMCID: PMC2596385          DOI: 10.1074/jbc.M804970200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Nuclear organization of DNA replication in primary mammalian cells.

Authors:  B K Kennedy; D A Barbie; M Classon; N Dyson; E Harlow
Journal:  Genes Dev       Date:  2000-11-15       Impact factor: 11.361

2.  Activation of SAPKs/JNKs and p38s in vitro.

Authors:  John M Kyriakis; Hong Liu; Deborah N Chadee
Journal:  Methods Mol Biol       Date:  2004

3.  c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells.

Authors:  O Potapova; M Gorospe; F Bost; N M Dean; W A Gaarde; D Mercola; N J Holbrook
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

Review 4.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

5.  The specificities of protein kinase inhibitors: an update.

Authors:  Jenny Bain; Hilary McLauchlan; Matthew Elliott; Philip Cohen
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

6.  Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells.

Authors:  Svetlana Avdulov; Shunan Li; Van Michalek; David Burrichter; Mark Peterson; David M Perlman; J Carlos Manivel; Nahum Sonenberg; Douglas Yee; Peter B Bitterman; Vitaly A Polunovsky
Journal:  Cancer Cell       Date:  2004-06       Impact factor: 31.743

7.  Inhibition of c-Jun NH2-terminal kinase activity improves ischemia/reperfusion injury in rat lungs.

Authors:  Makoto Ishii; Yukio Suzuki; Kei Takeshita; Naoki Miyao; Hiroyasu Kudo; Rika Hiraoka; Kazumi Nishio; Nagato Sato; Katsuhiko Naoki; Takuya Aoki; Kazuhiro Yamaguchi
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

8.  Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors.

Authors:  Hiromasa Tsuiki; Mehdi Tnani; Isamu Okamoto; Lawrence C Kenyon; David R Emlet; Marina Holgado-Madruga; Irene S Lanham; Christopher J Joynes; Kim T Vo; Albert J Wong
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

9.  c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 signaling pathways have divergent roles in CD8(+) T cell-mediated antiviral immunity.

Authors:  Nathalie Arbour; Denise Naniche; Dirk Homann; Roger J Davis; Richard A Flavell; Michael B A Oldstone
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

10.  The basic leucine zipper domain of c-Jun functions in transcriptional activation through interaction with the N terminus of human TATA-binding protein-associated factor-1 (human TAF(II)250).

Authors:  Tricia N Lively; Tuan N Nguyen; Shelly K Galasinski; James A Goodrich
Journal:  J Biol Chem       Date:  2004-04-15       Impact factor: 5.157

View more
  11 in total

1.  Thr-370 is responsible for CDK11(p58) autophosphorylation, dimerization, and kinase activity.

Authors:  Yayun Chi; Chunyi Zhang; Hongliang Zong; Yi Hong; Xiangfei Kong; Haiou Liu; Weiying Zou; Yanlin Wang; Xiaojing Yun; Jianxin Gu
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

2.  Measuring the constitutive activation of c-Jun N-terminal kinase isoforms.

Authors:  Ryan T Nitta; Shawn S Badal; Albert J Wong
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

Review 3.  Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases.

Authors:  Michael J Schnieders; Tamer S Kaoud; Chunli Yan; Kevin N Dalby; Pengyu Ren
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  H2O2 oxidation of cysteine residues in c-Jun N-terminal kinase 2 (JNK2) contributes to redox regulation in human articular chondrocytes.

Authors:  Kimberly J Nelson; Jesalyn A Bolduc; Hanzhi Wu; John A Collins; Elizabeth A Burke; Julie A Reisz; Chananat Klomsiri; Scott T Wood; Raghunatha R Yammani; Leslie B Poole; Cristina M Furdui; Richard F Loeser
Journal:  J Biol Chem       Date:  2018-09-06       Impact factor: 5.157

5.  MicroRNA-206 regulates cell movements during zebrafish gastrulation by targeting prickle1a and regulating c-Jun N-terminal kinase 2 phosphorylation.

Authors:  Xiuli Liu; Guozhu Ning; Anming Meng; Qiang Wang
Journal:  Mol Cell Biol       Date:  2012-05-21       Impact factor: 4.272

Review 6.  Interleukins in glioblastoma pathophysiology: implications for therapy.

Authors:  Y T Yeung; K L McDonald; T Grewal; L Munoz
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

7.  Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.

Authors:  Saurabh Sen; Philip J Webber; Andrew B West
Journal:  J Biol Chem       Date:  2009-10-13       Impact factor: 5.157

Review 8.  JNK Signaling in the Control of the Tumor-Initiating Capacity Associated with Cancer Stem Cells.

Authors:  Chifumi Kitanaka; Atsushi Sato; Masashi Okada
Journal:  Genes Cancer       Date:  2013-09

9.  Homodimerization of Nemo-like kinase is essential for activation and nuclear localization.

Authors:  Shizuka Ishitani; Kenji Inaba; Kunihiro Matsumoto; Tohru Ishitani
Journal:  Mol Biol Cell       Date:  2010-11-30       Impact factor: 4.138

10.  Osmostress induces autophosphorylation of Hog1 via a C-terminal regulatory region that is conserved in p38α.

Authors:  Inbal Maayan; Jonah Beenstock; Irit Marbach; Shira Tabachnick; Oded Livnah; David Engelberg
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.